Duloxetine
Product Images NDC 60760-559

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 60760-559). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by St. Mary's Medical Park Pharmacy, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Dulox (Duloxetine 60760 559 30)

Label for Duloxetine 60mg delayed-release capsules, USP, quantity 30. The label includes NDC 60760-559-30, manufacturer Zhejiang Huahai Pharmaceutical Co., Ltd. in China, and labeling by St. Mary's Medical Park Pharmacy, Oro Valley, AZ. The label instructs use as directed and storage at controlled room temperature 15°-30°C (59°-86°F).*

FDA Label Image

Image 1 (Image 01)

A line graph comparing the proportion of patients with relapse over time between Duloxetine treatment and Placebo groups. The x-axis shows time up to 250 units, and the y-axis shows the proportion of patients with relapse from 0 to 1. The Duloxetine group has a consistently lower relapse proportion than the Placebo group throughout the measured period.*

FDA Label Image

Image 2 (Image 02)

A line graph comparing the proportion of patients with relapse over time in days from randomization. It shows two lines representing treatment groups: placebo (dashed line) and duloxetine (solid line). The vertical axis measures the proportion of patients with relapse, and the horizontal axis measures time up to approximately 275 days.*

FDA Label Image

Image 3 (Image 03)

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline. It compares Duloxetine at 60 mg BID, 60 mg QD, 20 mg QD, and placebo, illustrating treatment effects on pain improvement over a range of percentages.*

FDA Label Image

Image 4 (Image 04)

A line graph depicting the percentage of patients improved versus percent improvement in pain from baseline for Duloxetine 60 mg twice daily (BID), Duloxetine 60 mg once daily (QD), and placebo. The graph shows trends comparing patient improvement across these three groups.*

FDA Label Image

Image 5 (Image 05)

A line graph showing the percentage of patients improved plotted against percent improvement in pain from baseline. The graph compares three groups: Duloxetine 60mg twice daily, Duloxetine 60mg once daily, and placebo, with Duloxetine groups showing higher improvement rates than placebo as percent pain improvement increases.*

FDA Label Image

Image 6 (Image 06)

A line graph depicting the percentage of patients improved versus percent improvement in pain from baseline for Duloxetine at 120mg, 60mg, and 20mg once daily doses, compared to placebo. The x-axis represents percent improvement in pain from baseline (0 to 100%), and the y-axis shows the percentage of patients improved (0 to 100%). The graph shows that all Duloxetine doses have a higher percentage of patients improved across most pain improvement levels compared to placebo.*

FDA Label Image

Image 7 (Image 07)

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline (BOCF). Two lines compare placebo and Duloxetine 60/120 mg once daily, with Duloxetine showing higher patient improvement percentages at most points.*

FDA Label Image

Image 8 (Image 08)

A line graph comparing the percentage of patients improved in pain from baseline between placebo and Duloxetine 60 mg once daily. The x-axis shows percent improvement in pain (BOCF) from 0 to 100%, and the y-axis shows the percentage of patients improved, ranging from 0 to 100%. Two lines represent the data: one for placebo and one for Duloxetine, illustrating higher improvement percentages with Duloxetine across most pain improvement levels.*

FDA Label Image

Image 9 (Image 09)

A line graph comparing the percentage of patients improved at various levels of pain improvement from baseline (BOCF) between placebo and Duloxetine 60/120 mg once daily. The x-axis represents percent improvement in pain, and the y-axis shows the percentage of patients improved. Duloxetine shows higher patient improvement percentages compared to placebo across the range.*

FDA Label Image

Chemical Structure (Structure)

Chemical structure of duloxetine hydrochloride showing its molecular framework, including a thiophene ring, naphthalene moiety, and an amine group associated with HCl.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.